Skip to main content
AVLNAvalyn Pharma Inc.Sell5.0·$28.40
SellModerate Confidence
Investment thesis

Avalyn Pharma combines heavy recent insider buying and high modeled upside with quality metrics below the engine's floor, a single extreme earnings miss, and institutional-constraint risk typical of a small, binary-outcome biotech.

Thesis pillars

  • Quality Below Engine Floor→Stable
  • Heavy Insider Buying↓Deteriorating
  • High Modeled Upside↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026· older than 90 days

Full reasoning →

Open full analysis

Avalyn Pharma Inc. (AVLN) Stock Analysis

Inst Constrain edge

SellVALUE-TRAP 1/5QualityModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $28.40: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to... Read more

$28.40+86.9% A.UpsideScore 5.0/10#148 of 240 Biotechnology
QualityF-score4 / 9FCF yield—
Stop $26.41Analyst target $53.07(−13% haircut)A.R:R 5.9:1
Analyst consensus$61.00+114.8%5 analysts with price targets
$53.07Analyst target
$28.40price
$61.00mean
$80

Sell if holding. Engine safety override at $28.40: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 116d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 16, 2026

Recent Developments — Avalyn Pharma Inc.

Latest item Nov 16, 2026 · Generated 2026-11-22T12:02:07Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 18, 2027116d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (2.5 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-11.0
Mkt Cap$1.3B
EV/EBITDA-8.1
Profit Mgn0.0%
ROE—
Rev Growth—
Beta—
DividendNone
Analysts with ratings11

Quality Signals

Piotroski F4/9MoatNarrow

Options Flow

P/C0.44bullish
IV84%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Piotroski F
4.4
Current Ratio
5.0
Moat
5.5
Quality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
1.1
Erm
5.0
Earnings Timing
5.0
Earnings concerns: 1B/2M

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Rsi
3.9
Macd
6.9
Ma Position
7.5
Volume distribution (falling OBV)
GatesMomentum 3.9<4.5INSIDER 0.74%=EXTREMEA.R:R 5.9 ≥ 1.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 116d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
61 · Neutral
↑ 20D MA↑ 50D MA↓ 200D MASupport $24.82Resistance $31.87

Price Targets

$26
$53
A.Upside+86.9%
A.R:R5.9:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (2.5 < 4.0)
! momentum at 3.9 (below the engine's 4.5 threshold)
! Insider activity: 0.74%=extreme

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-03-18 (116d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AVLN stock a buy right now?

Sell if holding. Engine safety override at $28.40: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $26.41. Score 5.0/10, moderate confidence.

What is the AVLN stock price target?

Analyst target: $53.07 (+86.9% upside). Prior stop was $26.41. Stop-loss: $26.41.

What are the risks of investing in AVLN?

Quality below floor (2.5 < 4.0).

Is AVLN overvalued or undervalued?

Avalyn Pharma Inc. trades at a P/E of N/A (forward -11.0). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about AVLN?

11 analysts rate AVLN, with a consensus score of 4.3/5. 5 analysts publish price targets averaging $61.

What does Avalyn Pharma Inc. do?Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare...

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · HALO (Halozyme Therapeutics, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I)
Home › Stocks › AVLN

Latest news

Latest News

Benzinga6d agoAnalyst
Fiscal.ai10d ago
Benzinga10d ago
Fiscal.ai19d ago
Benzinga51d agoAnalyst
Benzinga51d ago
Benzinga62d agoProduct
Benzinga75d agoProduct
Benzinga101d ago
Benzinga102d ago